BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 31, 2024
Breaking News: Topic alerts now available for all BioWorld subscribers
See today's BioWorld Science
Home
» Sudo raises series B to advance TYK2 inhibitors for MS, psoriasis
To read the full story,
subscribe
or
sign in
.
Neurology/Psychiatric
Sudo raises series B to advance TYK2 inhibitors for MS, psoriasis
Dec. 21, 2023
No Comments
Sudo Biosciences Inc. has closed a $116 million series B financing, with the funding raised to be used to advance two investigational TYK2 candidates into the clinic in 2024.
BioWorld Science
Dermatologic
Neurology/psychiatric
Series B
